Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
- PMID: 34815876
- PMCID: PMC8593787
- DOI: 10.1002/ccr3.5086
Patient and caregiver perspectives on transitioning to oral prophylaxis in the emerging hereditary angioedema treatment landscape
Abstract
This report describes the successful transition of two familial patients with HAE from injectable to oral prophylaxis without tapering prior therapy or employing a complex transition protocol.
Keywords: Haegarda; berotralstat; hereditary angioedema; shared decision‐making; switching; treatment burden.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Conflict of interest statement
Daniel F. Soteres, MD, MPH, is a clinical research investigator for Takeda and BioCryst and has accepted speaker or advisory board fees from Takeda, BioCryst, CSL Behring, and Pharming. Fellicia Grimes, BS, has no conflicts of interest to declare.
References
-
- Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132‐150. - PubMed
-
- Lumry WR, Settipane RA. Hereditary angioedema: epidemiology and burden of disease. Allergy Asthma Proc. 2020;41(6):S08‐S13. - PubMed
-
- Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond). 2019;80(7):391‐398. - PubMed
-
- CINRYZE (C1 esterase inhibitor [human]) for intravenous use, freeze‐dried powder for reconstitution [prescribing information]. 2018. Lexington, MA: Shire ViroPharma Incorporated.
Publication types
LinkOut - more resources
Full Text Sources
